307 related articles for article (PubMed ID: 34532080)
1. Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review.
Mittal SK; Abdo J; Adrien MP; Bayu BA; Kline JR; Sullivan MM; Agrawal DK
J Gastrointest Oncol; 2021 Aug; 12(4):1197-1214. PubMed ID: 34532080
[TBL] [Abstract][Full Text] [Related]
2. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Reavis KM; Morris CD; Gopal DV; Hunter JG; Jobe BA
Ann Surg; 2004 Jun; 239(6):849-56; discussion 856-8. PubMed ID: 15166964
[TBL] [Abstract][Full Text] [Related]
3. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
4. Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?
Schoppmann SF; Kristo I; Riegler M
Transl Gastroenterol Hepatol; 2018; 3():101. PubMed ID: 30701208
[TBL] [Abstract][Full Text] [Related]
5. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
6. Barrett's esophagus in 2016: From pathophysiology to treatment.
Martinucci I; de Bortoli N; Russo S; Bertani L; Furnari M; Mokrowiecka A; Malecka-Panas E; Savarino V; Savarino E; Marchi S
World J Gastrointest Pharmacol Ther; 2016 May; 7(2):190-206. PubMed ID: 27158534
[TBL] [Abstract][Full Text] [Related]
7. Chronic Obstructive Pulmonary Disease and the Risk of Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma: A Primary Care Case-Control Study.
Menon S; Nightingale P; Trudgill N
J Clin Gastroenterol; 2019; 53(10):e451-e455. PubMed ID: 31008868
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic therapy of esophageal premalignancy and early malignancy.
Nealis TB; Washington K; Keswani RN
J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
[TBL] [Abstract][Full Text] [Related]
9. The antioxidant response in Barrett's tumorigenesis: A double-edged sword.
Peng D; Zaika A; Que J; El-Rifai W
Redox Biol; 2021 May; 41():101894. PubMed ID: 33621787
[TBL] [Abstract][Full Text] [Related]
10. Origins of Metaplasia in Barrett's Esophagus: Is this an Esophageal Stem or Progenitor Cell Disease?
Zhang W; Wang DH
Dig Dis Sci; 2018 Aug; 63(8):2005-2012. PubMed ID: 29675663
[TBL] [Abstract][Full Text] [Related]
11. Animal Models of Barrett's Esophagus and Esophageal Adenocarcinoma-Past, Present, and Future.
Kapoor H; Lohani KR; Lee TH; Agrawal DK; Mittal SK
Clin Transl Sci; 2015 Dec; 8(6):841-7. PubMed ID: 26211420
[TBL] [Abstract][Full Text] [Related]
12. Barrett's Metaplasia Progression towards Esophageal Adenocarcinoma: An Attempt to Select a Panel of Molecular Sensors and to Reflect Clinical Alterations by Experimental Models.
Korbut E; Krukowska K; Magierowski M
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328735
[TBL] [Abstract][Full Text] [Related]
13. Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening.
Konda VJ; Cherkezyan L; Subramanian H; Wroblewski K; Damania D; Becker V; Gonzalez MH; Koons A; Goldberg M; Ferguson MK; Waxman I; Roy HK; Backman V
Endoscopy; 2013 Dec; 45(12):983-8. PubMed ID: 24019132
[TBL] [Abstract][Full Text] [Related]
14. Screening for Barrett's Esophagus: Balancing Clinical Value and Cost-effectiveness.
Patel A; Gyawali CP
J Neurogastroenterol Motil; 2019 Apr; 25(2):181-188. PubMed ID: 30827080
[TBL] [Abstract][Full Text] [Related]
15. Innovations in Screening Tools for Barrett's Esophagus and Esophageal Adenocarcinoma.
Bell MG; Iyer PG
Curr Gastroenterol Rep; 2021 Oct; 23(12):22. PubMed ID: 34654955
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
17. Precision care for Barrett's esophagus.
Triadafilopoulos G; Friedland S
Transl Gastroenterol Hepatol; 2018; 3():67. PubMed ID: 30363757
[TBL] [Abstract][Full Text] [Related]
18. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets for treatment of Barrett's esophagus.
Feagins LA; Souza RF
Dis Esophagus; 2005; 18(2):75-86. PubMed ID: 16053481
[TBL] [Abstract][Full Text] [Related]
20. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
